Apply for participation in the biobridge-2019 program
Arrange meeting
Experts
Dmitry Kravchenko
Doctor of chemical sciences, General Director of Chemical Diversity Research Institute
Project scientific novelty assessment, drug discovery early stages, preclinical, clinical and pharmaceutical drug development
Sir Konstantin Novoselov
Nobel laureate in physics, Professor at University of Manchester, Professor at National University of Singapore
Project scientific component and project novelty assessment
Josef Penninger
MD, Director of the Life Sciences Institute at the University of British Columbia in Canada
Project scientific component assessment, clinical and preclinical studies, oncology, osteoporosis
Ulrich Elling
PhD in Natural Sciences, Team Leader at Institute of Molecular Biotechnology, Vienna, Austria
Project scientific component assessment, molecular biology, genetics
Gerhard Puttner
Professor, Doctor of commercial sciences, entrepreneur, Owner/ CEO/ CD at DR.PUTTNER USP+ and Dr. Puttner Communications, lecturer at Vienna University of Economics and Business
Assessment of the team and project commercial potential, investment attractiveness assessment
Markus Huber
Entrepreneur, Vice-President for International Business at RDI Group Moscow, Growth Partner at Speedinvest Digital East, CEO at RDI Digital
Assessment of the team and project commercial potential, investment attractiveness assessment
Martin S. Denzel
Ph.D, Independent Research Group Leader at the Max Planck Institute for Biology of Ageing, co-founder of Acus Laboratories GmbH and
a scientific advisor to JLP Health GmbH
a scientific advisor to JLP Health GmbH
Assessment of scientific component and novelty of the project, clinical and preclinical studies, metabolic and genetic regulation of aging
Балакин К.В.
Doctor of chemical sciences,
Professor of Kazan Federal University
Professor of Kazan Federal University
Medical chemistry, drug discovery early stages, scientific novelty assessment
Dr. Cornelius Granig
CEO and Author, is a partner in the consulting industry, providing advice to clients in the area of digitalisation and cyber security
Project commercial potential and perspectives assessment, investment attractiveness assessment
Yan Ivanenkov
Candidate of Biological Sciences,
Head of Laboratory for Medical Chemistry and Bioinformatics at MIPT
Head of Laboratory for Medical Chemistry and Bioinformatics at MIPT
Insilico, medical chemistry
Vladimir Konyshev
General Director of Neurobotics Company, Deputy Head of NeuroNet NTI
Neuroassistant technologies, CNS
Aleksey Ilin
Doctor of chemical sciences,
Deputy general director for science and production at "API-technologies" company, ChemRar Group
Deputy general director for science and production at "API-technologies" company, ChemRar Group
Assessment of the scientific novelty of the project, early stages of drug discovery, development and production of API
Ruben Karapetyan
Candidate of biological Sciences,
Director of the Department of Pre-Clinical Research at ChemRar Group
Director of the Department of Pre-Clinical Research at ChemRar Group
Preclinical studies, cell biology, drug development
Natalia Vostokova
Candidate of pharmaceutical sciences,
Executive Director at "IPharma" LLC
Executive Director at "IPharma" LLC
Clinical studies
Alexander Melerzanov
Candidate of medical sciences, MD,
Dean of the Faculty of Biological and Medical Physics at MIPT
Dean of the Faculty of Biological and Medical Physics at MIPT
Cell technologies, cardiology, radionuclide medicine, clinical research
Yuri Krasnenkov
Director of Business Development Department at ChemRar Research Institute, Deputy General Director for Development at Chemical Diversity Research Institute
Assessment of teams and project commercial potential, investment attractiveness assessmet
Nikolay Merkin
Candidate of economical sciences,
General director of "ChemRar Ventures"
General director of "ChemRar Ventures"
Assessment of technology commercial potential and projects market prospects
Natalia Papazova
MBA, Executive Director of JSC Chemical Diversity Research Institute
Drug pharmaceutical development and production
Sergey Restevanyan
General director of BioIntegrator Company
Development and production of biotechnological drugs
Alexander Kaplan
Candidate of biological sciences,
Professor, Head of the Laboratory for Neurophysiology and Neurocomputer Interfaces, Moscow State University Faculty of Biology, Department of Human and Animal Physiology
Professor, Head of the Laboratory for Neurophysiology and Neurocomputer Interfaces, Moscow State University Faculty of Biology, Department of Human and Animal Physiology
Expertise of neurotechnologies, projects scientific novelty assessment
Nicolai Rodimov
Regional Manager for Central and Eastern Europe and CIS at the Vienna Business Agency
Project commercial potential assessment, investment attractiveness assessment
Irene Fialka
CEO of INiTS, Vienna's University Business Incubator (UBI), has a background in genetics/molecular biology and has worked with deeptech startups since 2004
Project commercial potential and perspectives assessment, investment attractiveness assessment
Prof. Pierluigi Nicotera
MD PhD, Scientific Director and Chairman, German Centre for Neurodegenerative Diseases, Professor of Neurodegeneration, University of Bonn, Germany
Assessment of scientific component and novelty of the project, cardiology, biochemical toxicology, neurodegeneration
Evgeny Gorodny
Entrepreneur, Investor, CEO & President Digital Medic GmbH, Inbiotech Gmbh, Member of the Board BioMedia LLC, MDK LLC
Project commercial potential and perspectives assessment, investment attractiveness assessment